Sugi Predict

Sugi Predict / Compounds / SCHEMBL275491

SCHEMBL275491

SCHEMBL275491

O=C1N=Cc2cc(-c3cnc(NC4CC4)c4ncnn34)ccc21

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK5 Q8IW41 3/20 0.43
▸ TTK P33981 1/20 0.40
▸ EGLN2 Q96KS0 2/20 0.37
▸ BRD4 O60885 6/20 0.34
▸ ATAD2 Q6PL18 6/20 0.34
▸ CHEK1 O14757 1/20 0.33
▸ MAPKAPK2 P49137 1/20 0.33
▸ FLT3 P36888 1/20 0.32
▸ ERN1 O75460 2/20 0.32
▸ PIM1 P11309 1/20 0.32
▸ PIM2 Q9P1W9 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ IKBKB O14920 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL275869 0.96 MAPKAPK5 (0.42) MAPKAPK5TTKEGLN2BRD4ATAD2
SCHEMBL274671 0.96 MAPKAPK5 (0.42) MAPKAPK5TTKBRD4ATAD2CHEK1
SCHEMBL274498 0.96 MAPKAPK5 (0.42) MAPKAPK5TTKEGLN2BRD4ATAD2
SCHEMBL275197 0.95 MAPKAPK5 (0.40) MAPKAPK5TTKEGLN2PIM1IKBKB
SCHEMBL273763 0.95 MAPKAPK5 (0.41) MAPKAPK5TTKEGLN2ALDH1A1TSHR
SCHEMBL273771 0.93 MAPKAPK5 (0.47) MAPKAPK5TTKFLT3ERN1PIM1
SCHEMBL274887 0.83 MAPKAPK5 (0.40) MAPKAPK5TTKEGLN2ERN1IKBKB
SCHEMBL275492 0.81 MAPKAPK5 (0.64) MAPKAPK5TTKFLT3
SCHEMBL274672 0.79 MAPKAPK5 (0.61) MAPKAPK5BRD4ATAD2FLT3USP2
SCHEMBL275911 0.78 FLT3 (0.43) MAPKAPK5TTKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133895-B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-13 — — US claimed
US-20090131446-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases GALAPAGOS, N.V. (BE) 2009-05-21 — — US claimed
US-8138193-B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-20 — — US disclosed
US-8133895-B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-13 — — US disclosed
US-20100240666-A1 FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ANDREWS MARTIN JAMES INGLIS 2010-09-23 — — US disclosed
US-20090131446-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases GALAPAGOS, N.V. (BE) 2009-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131446-A1 Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases NOD1, TNF, NOD2 MAPKAPK5 1247/4885TTK 4697/4885EGLN2 2621/4885
US-20100240666-A1 FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES RRP15, RARS2, RO60 MAPKAPK5 1958/4885TTK 4724/4885EGLN2 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.